Why Supplement Trials Are So Small

Read around the ingredients on any supplement panel and a pattern appears quickly. The studies are small. Forty participants, sometimes sixty, occasionally a hundred. Eight to twelve weeks. Often a single site in a single country.

Why they are that size. Money, mostly. A pharmaceutical trial is funded by a company that will hold a patent at the end of it. Nobody can patent cinnamon. That leaves university departments, small grants and occasionally an ingredient supplier, and none of those budgets stretches to a multi-thousand-person trial.

What a small trial can do. Detect a large effect. If an ingredient moves something substantially, forty people is often enough to see it. Small trials are genuinely useful for generating a signal.

What a small trial cannot do. Detect a modest effect reliably, rule out a modest harm, or tell you much about people unlike the participants. It also cannot survive the publication problem: a study finding nothing is less likely to be written up and published than one finding something, so the visible literature leans positive before anyone has read a word of it.

Why this matters on a blend label. It compounds with the arithmetic. A modest effect found in a small trial at a full dose gives you very little to reason from when the amount in front of you is an undisclosed fraction of that dose.

The honest position. Some names on this panel have a real literature behind them. Chromium has an established nutritional role rather than a set of trial results, which is a different and stronger position. Others have a handful of small studies, and three have almost nothing but traditional use. This site grades each one separately for exactly that reason, rather than averaging fourteen unequal evidence bases into a single confident sentence.